Logo image of ITCI

INTRA-CELLULAR THERAPIES INC (ITCI) Stock Analyst Ratings

NASDAQ:ITCI - Nasdaq - US46116X1019 - Common Stock - Currency: USD

126.9  -0.29 (-0.23%)

After market: 127.1 +0.2 (+0.16%)

Buy % Consensus

84

ChartMill assigns a Buy % Consensus number of 84% to ITCI. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 128.71. This target is 1.42% above the current price.
ITCI was analyzed by 22 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about ITCI.
In the previous month the buy percentage consensus was at a similar level.
ITCI was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
ITCI Historical Analyst RatingsITCI Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -97 -88 -79 -70 -61 -52 -43 -34 -25 -16 -7 5 10 15 20

Price Target & Forecast

Price Low Median Mean High 126.9087.87134.64128.71147.00 - -30.76% 6.10% 1.42% 15.84%
ITCI Current Analyst RatingITCI Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10
Up and Down Grades
Date Firm Action Rating
2025-01-31 Canaccord Genuity Downgrade Buy -> Hold
2025-01-22 RBC Capital Downgrade Outperform -> Sector Perform
2025-01-14 Piper Sandler Downgrade Overweight -> Neutral
2025-01-13 Needham Downgrade Buy -> Hold
2024-11-04 JP Morgan Maintains Overweight -> Overweight
2024-10-31 Needham Reiterate Buy -> Buy
2024-10-30 Needham Reiterate Buy -> Buy
2024-10-11 Morgan Stanley Maintains Overweight -> Overweight
2024-10-04 RBC Capital Maintains Outperform -> Outperform
2024-09-20 Cantor Fitzgerald Reiterate Overweight -> Overweight
2024-09-16 Cantor Fitzgerald Reiterate Overweight -> Overweight
2024-09-06 Piper Sandler Upgrade Neutral -> Overweight
2024-08-21 JP Morgan Maintains Overweight -> Overweight
2024-08-08 Cantor Fitzgerald Maintains Overweight -> Overweight
2024-08-08 UBS Maintains Neutral -> Neutral
2024-08-08 Needham Reiterate Buy -> Buy
2024-08-08 RBC Capital Maintains Outperform -> Outperform
2024-08-08 Goldman Sachs Maintains Neutral -> Neutral
2024-08-07 Needham Reiterate Buy -> Buy
2024-07-22 Needham Maintains Buy -> Buy
2024-06-25 UBS Downgrade Buy -> Neutral
2024-06-25 RBC Capital Reiterate Outperform -> Outperform
2024-06-21 Mizuho Maintains Buy -> Buy
2024-06-20 Canaccord Genuity Maintains Buy -> Buy
2024-06-18 Needham Maintains Buy -> Buy
2024-06-14 Cantor Fitzgerald Reiterate Overweight -> Overweight
2024-06-12 JP Morgan Maintains Overweight -> Overweight
2024-05-08 Needham Reiterate Buy -> Buy
2024-05-07 Needham Reiterate Buy
2024-04-24 Cantor Fitzgerald Reiterate Overweight -> Overweight